1 / 25

H1N1 A Discussion For Medical Personnel

H1N1 A Discussion For Medical Personnel. Bonita J. Sorensen, M.D., MBA Director Volusia County Health Department. H1N1 Points of Discussion. Why is this issue an important public health issue Current epidemiological information and the national, state and local level

declan
Download Presentation

H1N1 A Discussion For Medical Personnel

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. H1N1A Discussion For Medical Personnel Bonita J. Sorensen, M.D., MBA Director Volusia County Health Department

  2. H1N1Points of Discussion • Why is this issue an important public health issue • Current epidemiological information and the national, state and local level • Important CDC guidance you should be aware of • Priority groups for vaccination • Plans for vaccine safety monitoring • Who should be tested and who should be treated • Return to work guidance • Federal, state and local planning for vaccine distribution • When will vaccine be available locally • Payment Issues • Plans for mass vaccination • How you can help

  3. Influenza… is an old disease... it’s been with us for sometime…

  4. What are the consequences of yearly epidemics in U.S.A? > 36,000 die and 200,000 are hospitalized 5 to 20% of general population infected Nursing home attack rates of up to 60% 85% of flu-related deaths in ages > 65 Over $10 billion lost

  5. This rate of human and economic loss is our regular (normal) rate of loss due to minor changes in the viral protein structure (antigenic drift) What are the loss estimates when there are larger changes in the circulating viral structure (antigenic shift)?

  6. Our Historical ExperiencePast Flu Pandemics Credit: US National Museum of Health and Medicine 1918: “Spanish Flu” 1957: “Asian Flu” 1968: “Hong Kong Flu” A(H1N1) A(H2N2) A(H3N2) 20-40 m deaths 675,000 US deaths 1-4 m deaths 70,000 US deaths 1-4 m deaths 34,000 US deaths

  7. What might happen if we have a pandemic now? Mortality (death) rate of the new H1N1 virus not currently known. The following are estimates (depending on severity): Infected: 90 million US Based on 30% attack rate Hospitalized: 865,000 to 9.9 million US Deaths 209,000 to 1.9 million US $71-166 billion would be lost http://pandemicflu.gov/plan/pandplan.html, Accessed 24 August 2009

  8. How do pandemics happen?

  9. H1N1 Incidence NationallyAs of September 18, 2009 • 10,459 hospitalizations • 789 deaths

  10. H1N1 Swine Flu in Florida • Florida (as of September 18, 2009) • More than 3,000 cases have been reported (routine cases are no longer reportable) • 709 known hospital admissions • 87 deaths • Florida H1N1 info: www.myflusafety.com • Call 877 FLAFLU1 • The Bureau of EPI Weekly Surveillance Report:http://www.doh.state.fl.us/Disease_ctrl/epi/swineflu/index.html

  11. Local Epidemiological Surveillance

  12. Priority groups for vaccination • Advisory Committee on Immunization Practices (ACIP) recommended that novel H1N1 flu vaccine be made available first to the following five groups: • Pregnant women • People caring for infants under 6 months of age • Health care workers and emergency medical responders • Children and young adults from 6 months to 24 years • People aged 25 to 64 years with underlying medical conditions (e.g. asthma, diabetes) • Combined, these groups would equal approximately 159 million individuals http://www.flu.gov/faq/vaccines/2004.html, Accessed 24 August 2009

  13. ACIP Recommendations: Influenza A (H1N1) 2009 monovalent vaccine use • Prioritization within these 5 target groups might be necessary if initial vaccine availability is insufficient to meet demand (~42 mil) • Pregnant women • Household and caregiver contacts of children younger than 6 months of age • Health-care and emergency medical services personnel with direct patient contact • Children from 6 months through 4 years of age • Children and adolescents aged 5 through 18 years who have medical conditions associated with a higher risk of influenza complications

  14. ACIP Recommendations: Influenza A (H1N1) 2009 monovalent vaccine use • Vaccine should not be held in reserve for patients who already have received 1 dose but might require a second dose. • Simultaneous administration of inactivated vaccines against seasonal influenza viruses and pandemic (H1N1) 2009 virus IS PERMISSIBLE if different anatomic sites are used. • Simultaneous administration of live, attenuated vaccines against seasonal viruses and pandemic (H1N1) 2009 virus is NOT RECOMMENED. • All persons currently recommended for seasonal influenza vaccine, including those aged ≥65 years, should receive the seasonal vaccine as soon as it is available.

  15. Influenza A (H1N1) 2009 monovalent vaccine - safety monitoring Objectives of the safety monitoring response: • Identify clinically significant adverse events following receipt of vaccine in a timely manner • Rapidly evaluate serious adverse events following receipt of vaccine and determine public health importance • Evaluate if there is a risk of Guillain-Barré syndrome (GBS) associated with receipt of vaccine • Communicate vaccine safety information in a clear and transparent manner to all community stakeholders

  16. Influenza A (H1N1) 2009 monovalent vaccine - safety monitoring Methods: • Vaccine Adverse Event Reporting System (VAERS) will be the front-line monitoring system for collecting and analyzing voluntary reports of adverse events following receipt of vaccine

  17. Influenza A (H1N1) 2009 monovalent vaccine - safety monitoring Methods (continued): • Vaccine Safety Datalink • Collaborative effort between CDC and eight large managed care organizations • Vaccine Analytic Unit • Collaboration among the Department of Defense, CDC and the FDA • Emerging Infections Programs • A population-based network of CDC and 10 state health departments (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) • American Academy of Neurologists and CDC • Collaboration to enhance VAERS reporting of neurological events, including GBS • Clinical Immunization Safety Assessment (CISA) • Collaboration between CDC and 6 academic centers

  18. Who should be tested and who should be treated • Testing: • Recommended only for seriously ill (ICU) patients and those part of an epidemiological cluster: • A school, church, camp, day care, etc • No need to test everyone in a cluster, one or two will do • Treatment: • Tamiflu and Relenza are effective for H1N1 • These treatments are most effective if given within 24 hours of symptoms, but should be considered regardless of duration of illness in someone seriously ill http://www.cdc.gov/H1N1flu/antiviral.htm, Accessed 24 August 2009

  19. Who should be treated • The CDC has identified the same high risk groups for treatment that are recommended for treatment with seasonal flu. • Children younger than 5 years old. The risk for severe complications from seasonal influenza is highest among children younger than 2 years old. • Adults 65 years of age and older. • Persons with the following conditions: • Chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematological (including sickle cell disease), neurologic, neuromuscular, or metabolic disorders (including diabetes mellitus); • Immunosuppression, including that caused by medications or by HIV; • Pregnant women; • Persons younger than 19 years of age who are receiving long-term aspirin therapy; • Residents of nursing homes and other chronic-care facilities. http://www.cdc.gov/h1n1flu/recommendations.htm, Accessed 24 August 2009

  20. Return to work • Health care worker recommendations: • Healthcare personnel should not report to work if they have a febrile respiratory illness.In communities where swine influenza virus transmission is occurring, healthcare personnel who develop a febrile respiratory illness should be excluded from work for 7 days or until symptoms have resolved, whichever is longer. http://www.cdc.gov/h1n1flu/guidelines_infection_control.htm, Accessed 24 August 2009

  21. Return to work recommendations for your patients and the general public • CDC recommends that people with influenza-like illness remain at home until at least 24 hours after they are free of fever (100° F [37.8°C]), or signs of a fever without the use of fever-reducing medications. http://www.cdc.gov/h1n1flu/guidance/exclusion.htm, Accessed 26 Augsut 2009

  22. How You Can Help Us • Get vaccinated and recommend vaccinations to your staff. • The Volusia County Health Department will be reserving time every Friday in November and December to provide availability for your staff to be vaccinated at any of our locations

  23. How You Can Help Us • Volusia County Health Department Locations: • Daytona Beach • 1845 Holsonback Drive - Tel. 386-274-0500 • New Smyrna Beach • 711 W. Canal Street • Tel. 386-424-2065 • Deltona • 3151 Howland Blvd  • Tel. 386-789-7507 or 386-789-7508

  24. How You Can Help Us • DeLand Locations: • 909 N. Stone Street  • Tel. 386-822-6215 • Volusia County Health Department Women's Health Services Oakbrook Professional Centre 931 N. Spring Garden Avenue  Tel. 386-736-5320 

More Related